Ladenburg Thalmann & Co. Remains a Buy on Marinus (MRNS)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Marinus (MRNS), with a price target of $3. The company’s shares closed yesterday at $0.97, close to its 52-week low of $0.77.
According to TipRanks.com, Higgins is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -12.8% and a 28.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.
Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $13.05, implying a 1242.0% upside from current levels. In a report issued on July 23, Jefferies also maintained a Buy rating on the stock with a $4 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.54 and a one-year low of $0.77. Currently, Marinus has an average volume of 834.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.